Kalpit Patel
Stock Analyst at B. Riley Securities
(0.89)
# 3,752
Out of 4,876 analysts
55
Total ratings
33.33%
Success rate
-12.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $43.70 | +37.30% | 3 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $7.23 | +93.64% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $22.78 | +62.42% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $19.26 | +24.64% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.49 | +134.90% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $4.12 | +118.45% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.70 | +112.99% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.40 | +400.00% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $7.54 | +430.50% | 2 | Sep 20, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.34 | +782.35% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $14.32 | +39.66% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $1.94 | +1,446.39% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $7.11 | -15.61% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $9.10 | +295.60% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.12 | +4,145.28% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.18 | +1,425.42% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.95 | +156.41% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $7.00 | +1,328.57% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $12.40 | +504.84% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $43.70
Upside: +37.30%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $7.23
Upside: +93.64%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $22.78
Upside: +62.42%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $19.26
Upside: +24.64%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.49
Upside: +134.90%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $4.12
Upside: +118.45%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.70
Upside: +112.99%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.40
Upside: +400.00%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $7.54
Upside: +430.50%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.34
Upside: +782.35%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $14.32
Upside: +39.66%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $1.94
Upside: +1,446.39%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $7.11
Upside: -15.61%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $9.10
Upside: +295.60%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.12
Upside: +4,145.28%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.18
Upside: +1,425.42%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.95
Upside: +156.41%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $7.00
Upside: +1,328.57%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $12.40
Upside: +504.84%